相似文献
1
Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria.
Am J Trop Med Hyg. 2011 Feb;84(2):192-9. doi: 10.4269/ajtmh.2011.10-0363.
2
Drug repositioning in the treatment of malaria and TB.
Future Med Chem. 2011 Sep;3(11):1413-26. doi: 10.4155/fmc.11.95.
3
Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho.
Am J Trop Med Hyg. 2013 Jul;89(1):174-7. doi: 10.4269/ajtmh.13-0046. Epub 2013 May 13.
4
Combating antimicrobial resistance in malaria, HIV and tuberculosis.
Nat Rev Drug Discov. 2024 Jun;23(6):461-479. doi: 10.1038/s41573-024-00933-4. Epub 2024 May 15.
5
Practical Management of HIV-Associated Anemia in Resource-Limited Settings: Prospective Observational Evaluation of a New Mozambican Guideline.
AIDS Res Hum Retroviruses. 2016 Jan;32(1):12-25. doi: 10.1089/AID.2015.0030. Epub 2015 Aug 19.
6
Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.
Int J Tuberc Lung Dis. 2013 Mar;17(3):348-53. doi: 10.5588/ijtld.12.0100. Epub 2013 Jan 14.
7
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.00420-17. Print 2018 Feb.
8
Managing multiple and extensively drug-resistant tuberculosis and HIV.
Expert Opin Pharmacother. 2007 Jun;8(8):1035-7. doi: 10.1517/14656566.8.8.1035.
9
Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria.
PLoS Med. 2006 Jan;3(5):e102. doi: 10.1371/journal.pmed.0030102.
10
HIV drug resistance monitoring in resource constrained countries.
East Afr Med J. 2011 Jan;88(1):1-3.
引用本文的文献
1
Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis.
Front Pharmacol. 2021 Nov 24;12:718763. doi: 10.3389/fphar.2021.718763. eCollection 2021.
2
A seven-year surveillance of epidemiology of malaria reveals travel and gender are the key drivers of dispersion of drug resistant genotypes in Kenya.
PeerJ. 2020 Mar 12;8:e8082. doi: 10.7717/peerj.8082. eCollection 2020.
3
Molecular assays for antimalarial drug resistance surveillance: A target product profile.
PLoS One. 2018 Sep 20;13(9):e0204347. doi: 10.1371/journal.pone.0204347. eCollection 2018.
4
An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.
J Antimicrob Chemother. 2018 Jul 1;73(7):1737-1749. doi: 10.1093/jac/dky026.
5
Drying anti-malarial drugs in vitro tests to outsource SYBR green assays.
Malar J. 2015 Feb 21;14:90. doi: 10.1186/s12936-015-0600-z.
6
Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.
BMC Public Health. 2013 Apr 8;13:308. doi: 10.1186/1471-2458-13-308.
7
Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.
Antimicrob Agents Chemother. 2012 May;56(5):2612-8. doi: 10.1128/AAC.06145-11. Epub 2012 Feb 13.
8
Multidrug resistance among new tuberculosis cases: detecting local variation through lot quality-assurance sampling.
Epidemiology. 2012 Mar;23(2):293-300. doi: 10.1097/EDE.0b013e3182459455.
本文引用的文献
1
Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study.
BMC Public Health. 2010 Jun 21;10:355. doi: 10.1186/1471-2458-10-355.
2
Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed hiv type 1-infected patients in Shandong Province, China.
AIDS Res Hum Retroviruses. 2010 Jan;26(1):99-103. doi: 10.1089/aid.2009.0184.
3
Surveillance of HIV type 1 drug resistance among naive patients from Venezuela.
AIDS Res Hum Retroviruses. 2009 Dec;25(12):1329-33. doi: 10.1089/aid.2009.0118.
4
New medicines to improve control and contribute to the eradication of malaria.
Nat Rev Drug Discov. 2009 Nov;8(11):879-91. doi: 10.1038/nrd2972. Epub 2009 Oct 16.
5
Global resistance surveillance: ensuring antimalarial efficacy in the future.
Curr Opin Infect Dis. 2009 Dec;22(6):593-600. doi: 10.1097/QCO.0b013e328332c4a7.
6
Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV.
J Int AIDS Soc. 2009 Sep 18;12:20. doi: 10.1186/1758-2652-12-20.
7
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
Lancet. 2009 May 30;373(9678):1861-73. doi: 10.1016/S0140-6736(09)60331-7. Epub 2009 Apr 15.
8
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials.
J Infect Dis. 2009 Apr 1;199(7):1074-80. doi: 10.1086/597303.
9
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
PLoS One. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6.
10
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
Antivir Ther. 2008;13 Suppl 2:1-13.
Zotero 插件